Vertex Pharmaceuticals (NASDAQ: VRTX) certainly has the cash to acquire smaller biotechs. However, there’s also a possibility that the company could be an acquisition target itself. In this Motley Fool Live video recorded on June 23, Motley Fool contributors Keith Speights and Brian Orelli discuss what the odds are that Vertex is involved in a big acquisition within the next few years.